Follow
Catriona Jamieson
Catriona Jamieson
Professor of Medicine and Chief, Division of Regenerative Medicine, UC San Diego
Verified email at ucsd.edu
Title
Cited by
Cited by
Year
Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells
MF Clarke, JE Dick, PB Dirks, CJ Eaves, CHM Jamieson, DL Jones, ...
Cancer research 66 (19), 9339-9344, 2006
40882006
Granulocyte–macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson, LE Ailles, SJ Dylla, M Muijtjens, C Jones, JL Zehnder, ...
New England Journal of Medicine 351 (7), 657-667, 2004
19032004
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis
S Jaiswal, CHM Jamieson, WW Pang, CY Park, MP Chao, R Majeti, ...
Cell 138 (2), 271-285, 2009
17642009
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
C Zhao, A Chen, CH Jamieson, M Fereshteh, A Abrahamsson, J Blum, ...
Nature 458 (7239), 776-779, 2009
11602009
Stems cells and the pathways to aging and cancer
DJ Rossi, CHM Jamieson, IL Weissman
Cell 132 (4), 681-696, 2008
11002008
Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
E Passegué, CHM Jamieson, LE Ailles, IL Weissman
Proceedings of the National Academy of Sciences 100 (suppl_1), 11842-11849, 2003
10822003
Cancer stem cells and self-renewal
CA O'Brien, A Kreso, CHM Jamieson
Clinical cancer research 16 (12), 3113-3120, 2010
5862010
Chronic myeloid leukemia: mechanisms of blastic transformation
D Perrotti, C Jamieson, J Goldman, T Skorski
The Journal of clinical investigation 120 (7), 2254-2264, 2010
5282010
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
A Pardanani, JR Gotlib, C Jamieson, JE Cortes, M Talpaz, RM Stone, ...
Journal of Clinical Oncology 29 (7), 789-796, 2011
4972011
Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial
J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, ...
JAMA oncology 4 (5), 652-659, 2018
3912018
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia
T Sanda, LN Lawton, MI Barrasa, ZP Fan, H Kohlhammer, A Gutierrez, ...
Cancer cell 22 (2), 209-221, 2012
3692012
A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury
E Curtis, JR Martin, B Gabel, N Sidhu, TK Rzesiewicz, R Mandeville, ...
Cell stem cell 22 (6), 941-950. e6, 2018
3562018
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson, J Gotlib, JA Durocher, MP Chao, MR Mariappan, M Lay, ...
Proceedings of the National Academy of Sciences 103 (16), 6224-6229, 2006
3492006
Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation
AE Abrahamsson, I Geron, J Gotlib, KHT Dao, CF Barroga, IG Newton, ...
Proceedings of the National Academy of Sciences 106 (10), 3925-3929, 2009
2892009
Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers
C DeBoever, EM Ghia, PJ Shepard, L Rassenti, CL Barrett, K Jepsen, ...
PLoS computational biology 11 (3), e1004105, 2015
2412015
ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis
MA Zipeto, A Sadarangani, NPD Santos, L Balaian, HJ Chun, G Pineda, ...
Cell stem cell 19 (2), 177-191, 2016
2202016
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition
DJ Goff, A Sadarangani, HJ Chun, CL Barrett, M Krajewska, H Leu, ...
Cell stem cell 12 (3), 316-328, 2013
1992013
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia
Q Jiang, LA Crews, CL Barrett, HJ Chun, AC Court, JM Isquith, MA Zipeto, ...
Proceedings of the National Academy of Sciences 110 (3), 1041-1046, 2013
1822013
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors
I Geron, AE Abrahamsson, CF Barroga, E Kavalerchik, J Gotlib, JD Hood, ...
Cancer cell 13 (4), 321-330, 2008
1802008
Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia
MY Choi, GF Widhopf, EM Ghia, RL Kidwell, MK Hasan, J Yu, LZ Rassenti, ...
Cell Stem Cell 22 (6), 951-959. e3, 2018
1722018
The system can't perform the operation now. Try again later.
Articles 1–20